Abstract
Thyrotropin Suppressive Therapy in Differentiated Thyroid Cancer
Highlights
According to the double-risk-adapted strategy, suggested TSH levels in patient with Differentiated thyroid carcinoma (DTC) during follow-up is as follow
The risk for recurrence and progression in patients with DTC can be divided into three levels: low, intermediate and high risks, according to the American Thyroid Association (ATA) guidelines [7], and a similar assessment of the risk of adverse effects of L-T4 suppressive therapy can be divided into low, intermediate and high risks, summarized by Biondi and Cooper [9]
In patients with a high or intermediate risk of tumor progression and a high or intermediate risk of adverse effects from L-T4, the degree of TSH suppression should be adapted to the clinical situation, and cardiologic evaluation and bone density assessment should be underwent periodically [10,11]
Summary
According to the double-risk-adapted strategy, suggested TSH levels in patient with DTC during follow-up is as follow. In high-risk patients who have persistent disease, the American Thyroid Association (ATA) and European Thyroid Association (ETA) recommend that the serum TSH level be kept at
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
